Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up

• Published in: Journal of ocular pharmacology and therapeutics Vol. 31; no. 2; p. 106
• Main Authors: Nava-Castañeda, Angel, Ulloa-Orozco, Isabel, Garnica-Hayashi, Lilia, Hernandez-Orgaz, Joaquín, Jimenez-Martinez, Maria Carmen, Garfias, Yonathan
• Format: Journal Article
• Language: English
• Published: United States 01.03.2015
• Subjects: Adult; Aged; Angiogenesis Inhibitors - administration & dosage; Antibodies, Monoclonal, Humanized - administration & dosage; Bevacizumab; Corneal Neovascularization - drug therapy; Corneal Opacity - drug therapy; Female; Follow-Up Studies; Humans; Injections, Intraocular; Male; Middle Aged; Prospective Studies; Pterygium - drug therapy; Pterygium - pathology; Recurrence
• ISSN: 1557-7732
• DOI: 10.1089/jop.2014.0060

The aim of the study was to evaluate the effect of 3 subconjunctival bevacizumab injections in patients with an early corneal pterygium recurrence. This study was a nonrandomized single center trial. Patients with an early corneal pterygium recurrence were selected. All patients received 3 subconjunctival bevacizumab (2.5 mg/0.1 mL) injections (basal, 2 and 4 weeks) in the recurrence area of the pterygium. The corneal and corneal-conjunctival neovascularization areas and the corneal opacification area of each pterygium were determined using digital slit lamp pictures. Thirty-eight patients were enrolled into the study; all patients were injected within 3 months of the diagnosed pterygium recurrence. Interestingly, the bevacizumab injections had a significant effect (P<0.05) on the reduction of corneal, corneal-conjunctival area of neovascularization determined as pixels and on the corneal opacification area determined as mm(2) when comparing the basal values, to the values obtained after 15 days, 1 month, 3 months, 6 months, and 12 months after injections. The vascularized area in all recurrent pterygia and the corneal opacification area with this triple regimen of subconjunctival bevacizumab injections were reduced, which remained until the end of the study. These results suggest that bevacizumab subconjunctival injections could be useful to treat recurrent pterygium.